What Happened

Zealand Pharma presented additional data from its Phase 2 ZUPREME-1 trial at the ADA 2026 Scientific Sessions. The trial evaluated petrelintide, an amylin analog, for weight management in adults with obesity or overweight. Results showed clinically meaningful weight loss and improved cardiometabolic risk factors, with tolerability similar to placebo.

Who Is Affected

This development impacts individuals living with overweight or obesity, particularly those seeking long-term, effective, and well-tolerated treatment options. Healthcare providers specializing in obesity medicine and metabolic health will also be interested in this potential new therapy.

Market Impact

• Petrelintide could expand the obesity treatment market beyond current single-class therapies.
• Its favorable tolerability profile may improve treatment adherence and persistence.
• Roche and Zealand Pharma's collaboration strengthens their position in the metabolic health market.

What to Watch

Monitor the initiation of Phase 3 trials for petrelintide in late 2026. Full results from the ZUPREME-1 trial will be published later this year, providing further insights into its efficacy and safety. The advancement of petrelintide could signal a shift in obesity treatment paradigms.